Inflammation and Late-Life Depressive Symptoms: Inflammation et symptômes dépressifs chez les personnes âgées

Background Low-level systemic inflammation has been associated with late-life depressive symptoms. Whether individuals with higher inflammation derive preventive benefit from low-dose aspirin therapy is unknown. Methods We performed a post-hoc analysis of the ASPirin in Reducing Events in the Elderly (ASPREE) randomized, double-blind, placebo-controlled trial. Baseline high-sensitivity C-reactive protein (hsCRP) was measured in plasma and depressive symptoms were assessed annually using the Center for Epidemiologic Studies Depression 10 Scale (CES-D-10), with elevated symptoms defined as CES-D-10 ≥ 8. Participants with elevated depressive symptoms at baseline were excluded. We fitted population-averaged logistic generalized estimating equation models adjusted for baseline sociodemographic and lifestyle covariates, including an hsCRP × treatment interaction to test effect modification by aspirin. Results Higher baseline hsCRP was associated with increased odds of elevated depressive symptoms during follow-up (OR 1.07 per SD increase in hsCRP, 95% CI 1.03–1.11). Low-dose aspirin allocation did not modify the hsCRP-depressive symptoms association (interaction OR 1.02, 95% CI 0.94–1.10). Findings were similar after additional adjustment for comorbidity and other covariates. Conclusions In community-dwelling older adults during the ASPREE randomized trial period, higher baseline hsCRP was modestly associated with elevated depressive symptoms. There was no evidence that low-dose aspirin was associated with reduced risk of depressive symptoms among participants with higher baseline inflammation.

Authors

Institutions

Publication Details

Journal
The Canadian Journal of Psychiatry
Published
2026-11-21
DOI
https://doi.org/10.1177/07067437261500819
Primary Topic
Tryptophan and brain disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inflammation and Late-Life Depressive Symptoms: Inflammation et symptômes dépressifs chez les personnes âgées

Paul A Lacaze, Belayneh Mengist, Chenglong Yu, Mohammadreza Mohebbi et al.
The Canadian Journal of Psychiatry
Tryptophan and brain disorders
article

Inflammation and Late-Life Depressive Symptoms: Inflammation et symptômes dépressifs chez les personnes âgées

Paul A Lacaze, Belayneh Mengist, Chenglong Yu, Mohammadreza Mohebbi, Malcolm Forbes, Matthew JY Kang, John J. McNeil, Mojtaba Lotfaliany, A.M. Isvoranu, T L Nguyen, Robyn Woods, J E Neumann
article en

Abstract

Background Low-level systemic inflammation has been associated with late-life depressive symptoms. Whether individuals with higher inflammation derive preventive benefit from low-dose aspirin therapy is unknown. Methods We performed a post-hoc analysis of the ASPirin in Reducing Events in the Elderly (ASPREE) randomized, double-blind, placebo-controlled trial. Baseline high-sensitivity C-reactive protein (hsCRP) was measured in plasma and depressive symptoms were assessed annually using the Center for Epidemiologic Studies Depression 10 Scale (CES-D-10), with elevated symptoms defined as CES-D-10 ≥ 8. Participants with elevated depressive symptoms at baseline were excluded. We fitted population-averaged logistic generalized estimating equation models adjusted for baseline sociodemographic and lifestyle covariates, including an hsCRP × treatment interaction to test effect modification by aspirin. Results Higher baseline hsCRP was associated with increased odds of elevated depressive symptoms during follow-up (OR 1.07 per SD increase in hsCRP, 95% CI 1.03–1.11). Low-dose aspirin allocation did not modify the hsCRP-depressive symptoms association (interaction OR 1.02, 95% CI 0.94–1.10). Findings were similar after additional adjustment for comorbidity and other covariates. Conclusions In community-dwelling older adults during the ASPREE randomized trial period, higher baseline hsCRP was modestly associated with elevated depressive symptoms. There was no evidence that low-dose aspirin was associated with reduced risk of depressive symptoms among participants with higher baseline inflammation.

The Canadian Journal of Psychiatry
The Royal Melbourne Hospital (AU), Barwon Health (AU), Deakin University (AU), Universität Hamburg (DE), The University of Melbourne (AU), National University of Singapore (SG), Monash University (AU)
Deutsche Forschungsgemeinschaft, Monash University, National Institutes of Health, Medical Research Council, National Health and Medical Research Council, National Institute on Aging, National Cancer Institute
Good health and well-being
Tryptophan and brain disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon